A recent study indicates that individuals who come off new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who stop traditional lifestyle regimens.
Published data in a prominent health publication shows that while obese individuals can lose a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing these medications must be informed of the danger of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass within about 18 months.
Comparing Treatments
The research, which examined dozens of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with conventional dieting.
The team emphasize that people who shed pounds through dieting usually see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Doctors suggest the mechanism of the drugs is key to understanding the heightened rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines advise the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the treatment might need to be long-term.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.
Patient Accounts
Users who have stopped the jabs describe a intense return of hunger.
"I experienced something activating and you become extremely hungry," recalled a patient.
The struggle is compounded if individuals have not developed sustainable dietary or behavioural modifications during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone cure and maintained weight loss relies on combined lifestyle support.
